Johnson & Johnson vs Moderna, Inc.
JNJ vs MRNA — side-by-side comparison from reported financials. JNJ leads 7, MRNA leads 3 of 10 comparable metrics.
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
Moderna, Inc.
MRNA · Healthcare
$225.15+14.29%Strong
| Metric | JNJ | MRNA |
|---|---|---|
| Price | $261.79 | $225.15 |
| Market cap | $631B | $89.9B |
| Revenue (TTM) | $97.9B | $2.23B |
| Revenue growth | +5.6% | -53.4% |
| Net margin | 21.5% | -141.4% |
| Free cash flow | $22.2B | -$1.24B |
| Net cash (debt) | ($27.8B) | $5.21B |
| 1-year price return | +37.0% | +717.8% |
| P/E | 29.9 | 3.9 |
| P/E vs own history (cheap-side %) | 16% | 10% |
| Dividend yield | 2.00% | — |
| Return on equity | 26% | -39% |
| Altman Z-score | — | 13.40 |
| CV checks passed | 10 of 11 | 6 of 11 |
| Employees | 140,800 | 4,700 |
Full résumé-style profiles: JNJ CV · MRNA CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.